Key Takeaways Novo Nordisk gains FDA approval for Wegovy HD, showing 21% average weight loss in trials.NVO's obesity drug lineup may enhance competitiveness against Eli Lilly's Zepbound. Healthcare ETFs like OZEM offer diversified exposure to obesity drug market growth. The FDA recently approved higher-dose version of Novo Nordisk’s (NVO) obesity drug Wegovy, further expanding the drug giant’s footprint in the rapidly growing and fiercely competitive weight-loss market. Announced on March 19, 2026, the appr ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indication adds treatment and control of Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months. ...

Darmstadt, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- Employee volunteer program brings hands-on science learning to communities worldwideMore than 600.000 students reached and nearly 200.000 employee volunteer hours Ambitious 2035 goals aim to double student reach and expand global impact Merck, a leading science and technology company, marks the 10th anniversary of SPARK™, its global employee volunteer program that connects employees with communities through hands-on science learning and local service ...

Core Viewpoint - Merck announced the presentation of new clinical and real-world data supporting the long-term effectiveness of its 9-valent HPV vaccine, GARDASIL®9, and its 4-valent HPV vaccine, GARDASIL, against certain HPV-related cancers and diseases at the EUROGIN International conference [1]. Group 1 - The company is reaffirming the effectiveness of its HPV vaccines through new data [1]. - GARDASIL®9 is a 9-valent Human Papillomavirus vaccine, while GARDASIL is a 4-valent version [1]. - The presentation will take place at the EUROGIN International conference, highlighting the importance of the findings [1].

Key Takeaways MRK faces 2028 LOE for Keytruda, which generated $31.7B in 2025, around 55% of pharmaceutical sales.Merck sees $70B in potential non-risk-adjusted commercial opportunities from its pipeline by the mid-2030s.New drugs like Capvaxive posted $759M & Winrevair posted $1.4B sales in 2025 while supporting growth.Merck (MRK) is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2 ...

Core Insights - Artisan Value Fund's fourth-quarter 2025 performance was strong, with a return of 4.60%, outperforming the Russell 1000® Value Index which returned 3.81% [1] - The fund's annual return for 2025 was 14.28%, compared to 15.91% for the index, indicating effective investment discipline over three, five, and ten years [1] Company Highlights - Alphabet Inc. (NASDAQ:GOOG) was a significant contributor to the fund's performance, with a one-month return of -1.49% and a 52-week gain of 80.98% [2] - Alphabet's market capitalization stands at $3.647 trillion, reflecting its substantial market presence [2] Performance Drivers - The top three contributors to the fund's performance included Lam Research, Alphabet Inc., and Merck, each returning over 20% [3] - Alphabet's perception in the AI sector shifted positively, with the company transitioning from being viewed as "hunted" to a "hunter" in the AI race [3] - The antitrust ruling in September was less severe than anticipated, allowing Google to maintain its default search engine status on mobile devices [3] - Alphabet's Q3 results showed broad-based strength across all segments, with positive management commentary on competitive positioning and AI integration [3] - The launch of Gemini 3, Alphabet's latest AI model, and increased usage of TPUs for AI solutions provide a strategic advantage and revenue potential [3]

Group 1 - PepsiCo, Inc. is evaluated positively by Jim Cramer, emphasizing the importance of not selling good stocks due to short-term concerns, highlighting a 3.5% yield and effective leadership under CEO Ramon Laguarta [1] - The company produces a variety of products including beverages, snacks, cereals, dairy, and ready-to-drink items, with a focus on its snack division, Frito-Lay, which is currently facing challenges due to the impact of GLP-1 weight loss drugs [2] - Despite concerns regarding the snack division, PepsiCo's stock experienced a significant increase, closing almost five points higher, indicating potential positive market movements or reactions to broader industry performance [2] Group 2 - There is a belief that while PepsiCo has investment potential, certain AI stocks may offer greater upside potential and less downside risk, suggesting a shift in investment focus [3]

Core Insights - Merck & Co., Inc. is a global healthcare company facing competition from major pharmaceutical companies like Pfizer and Johnson & Johnson [1] - Mohit Bansal from Wells Fargo has set a price target of $150 for MRK, indicating a potential increase of 29.07% from its current price of $116.22 [1][6] Sales Performance - Gardasil vaccine sales dropped by 39% year over year in 2025, totaling $5.2 billion, primarily due to weak demand in China [2][6] - The decline in Gardasil sales is compounded by reduced demand in Japan and other vaccines, with management not expecting a recovery in 2026 [3] Stock Performance - MRK's current stock price is $115.48, reflecting a slight decrease of 0.63% from the previous day, with a market capitalization of approximately $285.5 billion [4][6] - Over the past year, MRK has experienced stock price volatility, with a high of $125.14 and a low of $73.31 [4] Market Activity - Today's trading volume for MRK is 687,521 shares, indicating investor interest and market activity [5]

Core Viewpoint - Merck & Co., Inc. is navigating challenges in the pharmaceutical industry, particularly with its Gardasil vaccine, while maintaining a strong market position and receiving positive ratings from analysts [1][3][4]. Group 1: Stock Performance - Merck's stock closed at $117.11, reflecting a 1.14% increase from the previous close, outperforming major indexes like the S&P 500, Dow, and Nasdaq [2][4]. - The stock has shown resilience despite a prior decline of 5.04%, indicating investor confidence ahead of the upcoming earnings report [2]. Group 2: Financial Outlook - Analysts predict an earnings per share (EPS) of -$0.57 for the upcoming earnings report on April 30, 2026, representing a significant year-over-year decline of 125.68% [2]. - Revenue is expected to increase by 3.09% to $16.01 billion, indicating some growth potential despite challenges [2][4]. Group 3: Product Challenges - Merck's Gardasil vaccine sales dropped by 39% in 2025, primarily due to reduced demand in China, impacting its partnership with Zhifei and halting shipments [3]. - There is no expected rebound in Gardasil sales for 2026, which may continue to pressure Merck's revenue streams [3]. Group 4: Analyst Ratings - Wells Fargo has reaffirmed an "Overweight" rating on Merck, raising the price target to $150, reflecting optimism about the company's future performance [1][4].

Core Viewpoint - Wells Fargo has raised its price target for Merck (MRK) to $150, driven by the potential of sacituzumab tirumotecan (sac-TMT) to replace chemotherapy in various cancer treatments, alongside the growth of KEYTRUDA and a robust pipeline of 80 Phase 3 studies [1] Group 1: Stock Performance and Predictions - Merck's stock has gained 23% over the past year and 8% year-to-date, currently trading below its 52-week high of $125.14 [1] - The Street consensus price target for Merck is $127.22, while Wells Fargo's target of $150 suggests significant upside potential [1] - Achieving a $150 price target would imply a market capitalization exceeding $283.4 billion, necessitating positive late-stage data for sac-TMT and sustained growth for KEYTRUDA [1] Group 2: Key Drivers of Stock Performance - Emerging growth portfolio: WINREVAIR, Merck's treatment for pulmonary arterial hypertension, generated $467 million in Q4 2025, reflecting a 133% year-over-year increase [1] - KEYTRUDA's revenue reached $8.337 billion in Q4 2025, up 6% year-over-year, with new FDA approvals expanding its indications [1] - The potential of sac-TMT to displace chemotherapy in multiple cancer types represents a significant commercial opportunity for Merck's oncology franchise [1] Group 3: Strategic Developments - The FDA awarded sac-TMT a Commissioner's National Priority Voucher, indicating strong regulatory support for its development [1] - A strategic financing agreement with Blackstone Life Sciences has been established to partially fund the development of sac-TMT [1]